Study of distinct protein profiles for early diagnosis of NSCLC using LCM and SELDI-TOF-MS

Yang, Shifeng; Nan, Yandong; Tian, Yuan; Zhang, Wei; Zhou, Bin; Bu, Lina; Huo, Shufen; Chen, Guoan; Yu, Jian; Zheng, Shu

doi:10.1007/s12032-008-9050-6

Cited by 10 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, SELDI-ToF-MS profiling has been applied in a few studies aimed to identify lung cancer biomarkers analyzing tissue [19-22] and serum samples [23-28]. Unfortunately, although the obtained results are quite promising, so far none of the discovered biomarker has already been validated for the clinical use.…”

Section: Introductionmentioning

confidence: 99%

Enriched sera protein profiling for detection of non-small cell lung cancer biomarkers

et al. 2011

View full text Add to dashboard Cite

BackgroundNon Small Cell Lung Cancer (NSCLC) is the major cause of cancer related-death. Many patients receive diagnosis at advanced stage leading to a poor prognosis. At present, no satisfactory screening tests are available in clinical practice and the discovery and validation of new biomarkers is mandatory. Surface Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (SELDI-ToF-MS) is a recent high-throughput technique used to detect new tumour markers. In this study we performed SELDI-ToF-MS analysis on serum samples treated with the ProteoMiner™ kit, a combinatorial library of hexapeptide ligands coupled to beads, to reduce the wide dynamic range of protein concentration in the sample. Serum from 44 NSCLC patients and 19 healthy controls were analyzed with IMAC30-Cu and H50 ProteinChip Arrays.ResultsComparing SELDI-ToF-MS protein profiles of NSCLC patients and healthy controls, 28 protein peaks were found significantly different (p < 0.05), and were used as predictors to build decision classification trees. This statistical analysis selected 10 protein peaks in the low-mass range (2-24 kDa) and 6 in the high-mass range (40-80 kDa). The classification models for the low-mass range had a sensitivity and specificity of 70.45% (31/44) and 68.42% (13/19) for IMAC30-Cu, and 72.73% (32/44) and 73.68% (14/19) for H50 ProteinChip Arrays.ConclusionsThese preliminary results suggest that SELDI-ToF-MS protein profiling of serum samples pretreated with ProteoMiner™ can improve the discovery of protein peaks differentially expressed between NSCLC patients and healthy subjects, useful to build classification algorithms with high sensitivity and specificity. However, identification of the significantly different protein peaks needs further study in order to provide a better understanding of the biological nature of these potential biomarkers and their role in the underlying disease process.

show abstract

Section: Introductionmentioning

confidence: 99%

Enriched sera protein profiling for detection of non-small cell lung cancer biomarkers

et al. 2011

View full text Add to dashboard Cite

show abstract

“…The cut off value depended on different statistic algorithm. Liao (26) study involved in statistic algorithm was SPSS 13.0, and studies of Yang (20) and Yang (17) were support vector machine (SVM). Remains were decision tree classification.…”

Section: Resultsmentioning

confidence: 99%

“…It is noted that SELDI-TOF-MS can also contribute to the ongoing human proteome studies, as proposed for the total proteins in the serum and other samples. SELDI-TOF-MS based protein profiling has been successfully applied in identification of different cancers and cancer-related biomarkers in diverse diagnostic samples as serum, plasma and tissue biopsies (20). When combined with radiological data, SELDI may bring patients new hopes in the early detection of NSCLC inside even before the onset of symptoms.…”

Section: Resultsmentioning

confidence: 99%

“…In Table III, two studies' (21,22) sample was cerebrospinal fluid, accordingly, cerebrospinal fluid may express less proteins. Conversely, Yang (20) researched protein profiles of tissue samples using laser capture micro dissection (LCM), and high values (sensitivity 100% and specificity 100%) were obtained. In Monari's (1) paper, two chips detected biomarkers and built different diagnosis model with low values.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The Value of Surface Enhanced Laser Desorption/Ionization-Time of Flight Mass Spectrometry at the Diagnosis of Non-Small Cell Lung Cancer: A Systematic Review

Jiang

Zhou²,

Jing

2014

Technol Cancer Res Treat

View full text Add to dashboard Cite

Numbers of studies used surface enhanced laser desorption/ionization-time of flight mass spectrometry (SELDI-TOF-MS) to find novel serum biomarkers for non-small cell lung cancer (NSCLC). It is arguable whether the SELDI technique has its value of diagnostic accuracy for NSCLC. The purpose of our study is to determine the diagnostic accuracy of SELDI-TOF-MS for diagnosing NSCLC. The Cochrane Central Register of Controlled Trials, MEDLINE, Pub Med, EMBASE, the Chinese Biomedical Literature Database, the China Academic Journals Full-text Database, and the Chinese Scientific Journals Database were searched systematically for potential studies. Reference lists of included studies and review articles were also reviewed. All studies that reported data on patients with a confirmed diagnosis of NSCLC and that compared the measurement of SELDI-TOF-MS with pathology standard were considered for inclusion. 11 studies were included in the systematic review. The ranges of the diagnostic value of SELDI-TOF-MS for NSCLC were as follows: sensitivity (SEN) was 0.70~1.00; specificity (SPE) was 0.68~1.00; positive likelihood ratio (PLR) was 2.23~23.14; negative likelihood ratio (NLR) was 0.04~0.43; and diagnostic odds ratio (DOR) was 5.17~621.0, respectively. SELDI-TOF-MS showed high accuracy in identifying NSCLC, and could be a potential screening tool for diagnosing NSCLC patients.

show abstract

“…Notably, >50% of patients diagnosed with NSCLC are at stage IIIB or IV disease, which is not only difficult to treat, but also increases pathologic material guiding systemic therapy (37). Therefore, a number of reports suggest that early diagnosis is beneficial for the treatment of NSCLC and may contribute to survival rate for patients in clinic (25,38). Previous research has indicated that contrast-enhanced ultrasound has been widely applied in NSCLC diagnosis (39).…”

Section: Discussionmentioning

confidence: 99%

Ultrasonic diagnosis combined with targeted ultrasound contrast agent improves diagnostic sensitivity of ultrasonic for non‑small cell lung cancer patients

Zhang

Chu

2018

Exp Ther Med

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is one of the most prevalent human cancers, which is known for local growth, easily migration, long-distance invasion and reoccurrence. Targeted ultrasound (US) contrast combined with ultrasound for lung cancer diagnosis has been applied in the clinic. In the present study, a novel targeted ultrasound contrast agent containing chistosan/FeO-parceled bispecific antibody (TcBab) targeting carcino-embryonic antigen, vascular endothelial growth factor receptor was introduced, and the diagnostic accuracy and sensitivity was investigated in patients with NSCLC. A total of 384 patients with suspected NSCLC were recruited to investigate the accuracy of TcBab-ultrasound (TcBab-US) and ultrasound. Results demonstrated that TcBab-US improved sensitivity and may provide a novel protocol for diagnosing tumors in patients with suspected NSCLC at an early stage. Data analysis demonstrated that TcBab-US diagnosed 154 suspected patients with NSCLC, whereas ultrasound only diagnosed 84 suspected patients with NSCLC out of a total of 384 patients with suspected NSCLC (P<0.01). A dosage experiment revealed that the optimal dose of TcBab was 5 mg/kg for NSCLC patients. Pharmacodynamics analysis showed that TcBab may be metabolized within 16 h in serum of patients. Notably, early diagnosis determined by TcBab-US contributed to improvement of survival for NSCLC patients as determined by a comparison of the survival rate with the survival rate of patients who did not receive TcBab (P<0.05). In conclusion, these investigations suggested that TcBab improves the accuracy and diagnostic confidence of ultrasonic for the diagnosis of early-stage NSCLC, and may have potential application value in the clinic.

show abstract

Study of distinct protein profiles for early diagnosis of NSCLC using LCM and SELDI-TOF-MS

Cited by 10 publications

References 14 publications

Enriched sera protein profiling for detection of non-small cell lung cancer biomarkers

Enriched sera protein profiling for detection of non-small cell lung cancer biomarkers

The Value of Surface Enhanced Laser Desorption/Ionization-Time of Flight Mass Spectrometry at the Diagnosis of Non-Small Cell Lung Cancer: A Systematic Review

Ultrasonic diagnosis combined with targeted ultrasound contrast agent improves diagnostic sensitivity of ultrasonic for non‑small cell lung cancer patients

Contact Info

Product

Resources

About